Enarodustat ( JTZ-951 ) is an orally-active HIF-PH inhibitor with an EC50 of 0.22 Μm, that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism. The Phase 3 clinical studies confirmed efficacy in anemic patients with non-dialysis dependent CKD and dialysis dependent CKD. Furthermore, the favorable tolerability profile on safety of enarodustat was obtained during the studies
For research use only. We do not sell to patients.